Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value (Tables)

Fair Value (Tables)

9 Months Ended

Sep. 30, 2021

Schedule of financial assets measured at fair value on a recurring basis

Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):


	Assets at Fair Value as of September 30, 2021
	Level 1		Level 2		Level 3		Total
Money market funds	$	25,794	$	—	$	—	$	25,794
U.S. treasury bills		—		37,991		—		37,991
Government-sponsored enterprise securities		—		14,735		—		14,735
Corporate bonds and commercial paper		—		62,016		—		62,016
Total	$	25,794	$	114,742	$	—	$	140,536


	Assets at Fair Value as of December 31, 2020
	Level 1		Level 2		Level 3		Total
Money market funds	$	19,487	$	—	$	—	$	19,487
U.S. treasury bills		—		10,034		—		10,034
Government-sponsored enterprise securities		—		4,920		—		4,920
Corporate bonds and commercial paper		—		20,898		—		20,898
Total	$	19,487	$	35,852	$	—	$	55,339